RxDoctor Payments Data

Rachel Young, APRN

Family Medicine · Tulsa, OKNPI 1952031577

Payments from drug & device makers

$1,895in general payments, 2019–2025

Across 92 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$943
  • AstraZeneca$267
  • Bayer$156
  • Pharmacosmos Therapeutics Inc.$105
  • Organon$79
  • Lundbeck LLC$69
  • plus $276 from 11 others

What the payments were for

  • Food & beverage$1,895100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,895 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$27,145
Medicare patients
152
Services billed
648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin52$56,469
VraylarCariprazine Hcl31$47,881
MounjaroTirzepatide42$46,047
OzempicSemaglutide44$45,085
EliquisApixaban31$24,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,617
FarxigaDapagliflozin Propanediol12$11,628
Gabapentin71$1,549
Omeprazole59$1,408
Albuterol Sulfate HfaAlbuterol Sulfate47$1,082
Hydroxyzine Hcl47$1,048
Atorvastatin Calcium48$827
Tamsulosin Hcl52$724
Lisinopril70$624
Fenofibrate44$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$943$47,88131 claims
Lilly USA, LLCMounjaro$19$46,04742 claims
Novo NordiskOzempic$30$45,08544 claims
GSKTrelegy Ellipta$47$15,61723 claims
AstraZenecaFarxiga$267$11,62812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →